Lunit vs OpenEvidence vs Recursion Pharmaceuticals vs Tempus AI
A side-by-side look at scores, pricing and features — with RECATOOLS' ASEAN-aware verdict for each.
Lunit
KOSDAQ-listed Korean AI for breast and lung cancer screening
Visit
|
|
Recursion Pharmaceuticals
Publicly traded techbio company (NASDAQ: RXRX) industrialising drug di...
Visit
|
|
|
|---|---|---|---|---|
| RECATOOLS Score | 6.7 / 10 | 7.8 / 10 | 7 / 10 | 8.2 / 10 |
| Capability | — | |||
| Value for money | — | |||
| Ease of use | — | |||
| ASEAN readiness | — | |||
| API quality | — | |||
| Pricing | Enterprise | Freemium | Enterprise | Enterprise |
| Free tier | — | Free for all verified US clinicians (NPI required); ad-supported | — | No free tier; enterprise contracts only |
| Paid from | — | Enterprise tier in development; pricing undisclosed — contact sales | Partnership / collaboration deals (not a self-serve product) | Custom enterprise contracts; multi-year data-licensing subscriptions (price not publicly disclosed) |
| Has API | ✗ | ✗ | ✗ | ✓ |
| Open source | ✗ | ✗ | ✗ | ✗ |
| Free to use | ✗ | ✓ | ✗ | ✗ |
| Users | — | ~860,000 verified US clinicians (June 2026) | — | ~50% of US oncologists; 4,500+ hospital integrations; 40M+ clinical records |
| Founded | 2013 | 2022 | 2013 | 2015 |
| Maker | — | Daniel Nadler (CEO), Zachary Ziegler (CTO) | Chris Gibson | Tempus AI, Inc. (independent, Nasdaq: TEM) |
| Verdict | Lunit is the most clinically validated medical-AI company to come out of Korea, and one of the few in the category with real revenue rather than just pilot deployments — Q1 2026 revenue hit 24 billion won, up nearly 25%... |
OpenEvidence is genuinely useful for US clinicians: free, citation-backed answers pulled from NEJM, JAMA, and AMA guidelines, funded by pharma advertising instead of subscriptions. Growth has been extraordinary — over 69... |
What this is for: AI-driven, industrial-scale drug discovery combining large biological datasets, automated experiments and its own supercomputing. Who this is for: Pharmaceutical and biotech partners, plus investors in... |
Tempus AI sits on one of the more defensible data moats in health AI — a self-reinforcing loop of clinical sequencing, molecular data, and real-world outcomes that's hard for pure-software competitors to replicate. Q1 20... |
| Full review → | Full review → | Full review → | Full review → |
Comparisons cover up to 4 tools. Scores are RECATOOLS editorial assessments; verify current pricing on each vendor's site.